Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Weill Medical College of Cornell University
Hackensack Meridian Health
Hackensack Meridian Health
Hackensack Meridian Health
Celgene
Janssen Research & Development, LLC
Dana-Farber Cancer Institute
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products R&D, Inc.
Acerta Pharma BV
Acerta Pharma BV
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Bristol-Myers Squibb
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Janssen Research & Development, LLC
Mayo Clinic
City of Hope Medical Center
M.D. Anderson Cancer Center
University of Maryland, Baltimore
GlaxoSmithKline
Celgene
GlaxoSmithKline
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Sellas Life Sciences Group
Columbia University
Mayo Clinic
Emory University
Jazz Pharmaceuticals
Altor BioScience
Sanofi
Juno Therapeutics, a Subsidiary of Celgene
Kyowa Kirin Co., Ltd.
Stemline Therapeutics, Inc.
GlaxoSmithKline
Sanofi
Poseida Therapeutics, Inc.
City of Hope Medical Center
GlaxoSmithKline
Duke University
City of Hope Medical Center
Hoosier Cancer Research Network
Celgene
University of Nebraska
Teva Branded Pharmaceutical Products R&D, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins